Creating a tumor-resistant microenvironment Cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo

Cell Cycle

Volumn 12, Issue 3, 2013, Pages 480-490

  Al Zoubi, Mazhar ^a,b   Salem, Ahmed F ^a   Martinez Outschoorn, Ubaldo E ^b   Whitaker Menezes, Diana ^b   Lamb, Rebecca ^c   Hulit, James ^c   Howell, Anthony ^c   Gandara, Ricardo ^c   Sartini, Marina ^d   Arafat, Hwyda ^e   Bevilacqua, Generoso ^a   Sotgia, Federica ^b,c   Lisanti, Michael P ^b,c  

^a UNIVERSITY OF PISA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Apoptosis; Autophagy; Breast cancer; Cancer prevention; Cellular therapy; Fibroblast mediated delivery; Mitochondrial dysfunction; Tumor cell engraftment; Tumor growth; Tumor necrosis factor (TNF)

Indexed keywords

COLLAGEN TYPE 6; CYCLOOXYGENASE 2; GELATINASE A; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; P21 ACTIVATED KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; AUTOPHAGY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER TRANSPLANTATION; CELL DEATH; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ENERGY TRANSFER; EPITHELIUM CELL; FIBROBLAST; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARACRINE SIGNALING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; STROMA CELL; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

MUS;

EID: 84875527022     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23370     Document Type: Article

References (28)

1. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119: 651-65; PMID:22053109; http://dx.doi.org/10.1182/blood- 2011-04-325225
2. Roberts NJ, Zhou S, Diaz LA Jr., Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011; 2: 739-51; PMID:22036896
3. Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 2012; 64: 21-32; PMID:21898354; http://dx.doi.org/10.1002/art.30653
4. Cassaday RD, Malik JT, Chang JE. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 2011; 11: 289-92; PMID:21658658; http://dx.doi.org/10.1016/j.clml.2011.03.018
5. Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011; 38: 1552-62; PMID:21572154; http://dx.doi.org/10.3899/jrheum.100995
6. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035-50; PMID:21315483; http://dx.doi.org/10.1016/j.jaad.2010.09.734
7. Ashkenazi A, Holland P, Eckhardt SG. Ligandbased targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-30; PMID:18640940; http://dx.doi.org/10.1200/JCO.2007.15.7198
8. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008; 8: 124-31; PMID:18336195; http://dx.doi.org/10.2174/156800908783769346
9. Grosse-Wilde A, Kemp Cj.Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Res 2008; 68: 6035-7; PMID:18676822; http://dx.doi.org/10.1158/0008-5472.CAN-08-0078
10. Secchiero P, Zauli G. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008; 15: 42-8; PMID:18043245; http://dx.doi.org/10.1097/MOH.0b013e3282f15fa6
11. ten Hagen TL, Seynhaeve AL, Eggermont AM. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev 2008; 222: 299-315; PMID:18364010; http://dx.doi.org/10.1111/j.1600-065X.2008. 00619.x
12. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008; 29: 1275-88; PMID:18954521; http://dx.doi.org/10.1111/j. 1745-7254.2008.00889.x
13. Uchibori R, Tsukahara T, Mizuguchi H, Saga Y, Urabe M, Mizukami H, et al. NFκB Activity Regulates Mesenchymal Stem Cell Accumulation at Tumor Sites. Cancer Res 2013; 73: 364-72; PMID:23066037
14. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115: 1163-76; PMID:15841211
15. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279: 51630-46; PMID:15355971; http://dx.doi.org/10.1074/jbc. M409214200
16. Chiavarina B, Martinez-Outschoorn UE, Whitaker- Menezes D, Howell A, Tanowitz HB, Pestell RG, et al. Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle 2012; 11: 3280-9; PMID:22894905; http://dx.doi.org/10.4161/cc.21643
17. Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012; 11: 3599-610; PMID:22935696; http://dx.doi.org/10.4161/cc.21884
18. Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, et al. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle 2011; 10: 4208-16; PMID:22033146; http://dx.doi.org/10.4161/cc.10.24. 18487
19. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells "fuel" cancer cell mitochondria. Cell Metab 2012; 15: 4-5; PMID:22225869; http://dx.doi.org/10.1016/j.cmet.2011.12.011
20. Sotgia F, Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Lisanti MP. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res 2011; 13:213; PMID:21867571; http://dx.doi.org/10.1186/bcr2892
21. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7: 423-67; PMID:22077552; http://dx.doi.org/10.1146/annurev-pathol-011811-120856
22. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: cancerassociated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal 2012; 16: 1264-84; PMID:21883043; http://dx.doi.org/10.1089/ars. 2011.4243
23. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, et al. Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 2010; 10: 537-42; PMID:20861671; http://dx.doi.org/10.4161/cbt.10.6.13370
24. Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, et al. Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer". Cell Cycle 2011; 10: 2440-9; PMID:21734470; http://dx.doi.org/10.4161/cc.10.15. 16870
25. Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, et al. Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle 2011; 10: 2059-63; PMID:21654190; http://dx.doi.org/10.4161/cc.10. 13.16233
26. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1: 1074-83; PMID:23170255; http://dx.doi.org/10.4161/onci.20897
27. Stölting MN, Ferrari S, Handschin C, Becskei A, Provenzano M, Sulser T, et al. Myoblasts inhibit prostate cancer growth by paracrine secretion of TNF alpha. J Urol 2012; In press; PMID:23123370; http://dx.doi.org/10.1016/j. juro.2012.10.071
28. Lee RH, Yoon N, Reneau JC, Prockop Dj.Preactivation of Human MSCs with TNFα Enhances Tumor- Suppressive Activity. Cell Stem Cell 2012; 11: 825-35; PMID:23142520; http://dx.doi.org/10.1016/j.stem.2012.10.001